U.S. Stock Market Movers: Moderna surged on October 21st due to cancer vaccine progress and target price upgrade
Bitget异动解读2026/10/21 19:41Moderna October 21st Surge Explained
Keywords: Cancer vaccine progress, target price raise
1. On October 21st, reports stated that the personalized cancer vaccine intismeran autogene, developed by Moderna in collaboration with Merck, combined with Keytruda, significantly improved recurrence-free survival in some melanoma patients; the full phase III data is scheduled to be released on October 24th.
2. On October 21st, TD Cowen raised Moderna's target price from $40 to $90.
(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tesla CFO: Energy business gross margin rises to 33.1%
Tesla raises its capital expenditure guidance for this year to $20 billion
Elon Musk said production will be increased to meet demand.
Elon Musk says Tesla aims to produce 5 million cars annually by around 2030.
